Liliana Ascione

🚨 OncoAlert GU Faculty TOP 🔟 abstracts in GU Oncology for #ASCO26 Truly honored and proud to be among the Leads 🗺 Selected by our leads and finalized through a Delphi voting process with senior GU experts across 🌎🌏🌍 #ProstateCancer #KidneyCancer #BladderCancer. 💛 A snapshot of what will shape GU oncology at #ASCO26, and what we all hope will translate into better, more thoughtful care for our patients 👇 1️⃣ LBA5007 — TALAPRO-3 Talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC with HRR alterations 2️⃣ LBA1 — PROTEUS (final Phase 3) Perioperative apalutamide + ADT vs ADT in high-risk localized/locally advanced prostate cancer 3️⃣ 5001 — ENZAMET genomic analysis Decipher >0.85 to identify benefit from adding docetaxel to ADT + enzalutamide 4️⃣ LBA4511 — KEYNOTE-564 ctDNA (RCC) ctDNA dynamics in RCC treated with adjuvant pembrolizumab vs placebo 5️⃣ 4502 — RAMPART (Phase 3 RCT, RCC) Durvalumab vs active monitoring after resection in RCC 6️⃣ 4500 — RADICAL (A031801, RCC bone mets) Radium-223 + cabozantinib in RCC with bone metastases 7️⃣ 4507 — EV-302 long-term follow-up (LA/mUC) Enfortumab vedotin + pembrolizumab vs chemotherapy in 1L LA/mUC 8️⃣ 4513 — AMBASSADOR (A031501, MIBC) HRQoL with adjuvant pembrolizumab vs observation in high-risk MIBC 9️⃣ 4503 — SAKK 06/19 (MIBC) Perioperative intravesical rBCG + chemo-IO strategy (primary analysis) 🔟 4510 — KEYNOTE-905 (cisplatin-ineligible MIBC) HRQoL with perioperative enfortumab vedotin + pembrolizumab ✨ Recurring theme: precision intensification 🧬 + ctDNA integration 🩸 + patient-centered outcomes (QoL) 🧠 + practice-changing frontline standards 🔥 And the key question: how do we implement this thoughtfully and equitably in real-world care? Leads @nataliagandur @scocmem @AmandaNizamMD @WeOncologists Senior Faculty @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @Silke_Gillessen @tompowles1 @AndreaNecchi @cdanicas @AOmlin Pinging @crisbergerot @HHammersMD @ravikanesvaran @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @brian_rini #GUOncology #OncoAlert #ASCO26 #KidneyCancer #BladderCancer #ProstateCancer

First time at @ASCO annual meeting? I prepared a short visual guide for first-time attendees: how to plan your schedule, choose the right sessions, and make the most of your time in Chicago. Chicago, see you soon. 🎡 #ASCO26 #Oncology #CancerResearch @ASCOPres @ASCOPost @ASCOTECAG

The American Society of Clinical Oncology (@ASCO) meeting is where data is presented. Our friends at Pulse Health Sciences is where experts decide what to do with it. Blueprint with convene nationally recognized faculty across GU & Breast Cancer to shape how emerging research is understood and applied in real-world care. If you're heading to Chicago, we hope you'll join us: HR+ Breast Cancer: ◆ Saturday, May 30 at 6:30pm-9:00pm at Barrio | 65 W Kinzie St, Chicago, IL 60654 ◆ Program Chair: Seth Wander, MD, PhD ◆Panelists: Jason A. Mouabbi, MD, Mark Pegram, MD, Megan Kruse, MD, Gregory Vidal, MD, PhD HER2+ & Metastatic Triple-Negative Breast Cancer: ◆ Sunday, May 31 at 6:30pm-9:00pm at Morgan’s on Fulton | 950 W Fulton St, Chicago, IL 60607 ◆ Program Chair: @hoperugo MD ◆ Panelists: Reshma Mahtani, DO, Nan Chen, MD, Irene Kang, MD, @nlinmd MD Genitourinary Cancer, in collaboration with AUC3 ◆ Sunday, May 31 at 6:30pm-9:00pm at Morgan’s on Fulton | 950 W Fulton St, Chicago, IL 60607 ◆ Program Chairs: @DrRanaMcKay and @DrChoueiri (c’est moi) of @AUC3_Official ◆ Panelists: @TiansterZhang , @Galsky @neerajaiims @montypal Register here: lnkd.in/dtHvm-hd Learn more at lnkd.in/dbVwB5CX #ASCO2026 #GUOncology #KidneyCancer #ProstateCancer #BladderCancer #BreastCancer #Blueprint #Oncology #Pulse #Community

📣 #ASCO26 a few days away! Here the 🥇top10 for genitourinary #cancer 👉 @ASCO @OncoAlert @DrChoueiri @NazliDizman @nataliagandur @neerajaiims @DrYukselUrun @BourlonMaite @DrRanaMcKay @DanaFarber_GU

Development and internal validation of a novel prognostic score for real-world #RCC patients eligible for adjuvant therapy. Presented by Rocco Simone Flammia, MD @SapienzaRoma. #AUA26 written coverage by @RKSayyid @UAUrology > bit.ly/4dPhPxQ @AmerUrological

K-COMPASS study investigates ctDNA and KIM-1 in oligometastatic #KidneyCancer. @ChadTangMD @UTMDAnderson joins @l_ballas @CedarsSinai to discuss K-COMPASS, a prognostic model for oligometastatic clear cell #RenalCellCarcinoma patients receiving radiation without systemic therapy. #WatchNow > bit.ly/4rQiBOY

In prostate cancer, protecting bone health is not extra care. It is vital part of the care. @OpenMedicineHQ @scserendipity1 @MedwatchKate @AlisonBirtle

JUST IN: @FDA approves datopotamab deruxtecan/TROP-2 ADC (Datroway, @DaiichiSankyo) for metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/L1 inhibitor. Trial led by @RebeccaDSing & published @Annals_Oncology #ESMO25 fda.gov/drugs/resource…

DatoDXd now @US_FDA ✅ in 1L mTNBC in PDL1 negative/IO ineligible based off TROPION-Breast02 - mPFS 10.8 vs 5.6mos (HR: 0.57) - mOS 23.7 vs. 18.7mos (HR: 0.79) - ORR 62.5% vs. 29.3% - Common AEs: mucositis & occular AEs #OncTwitter #bcsm @OncUpdates

Our latest in @NatRevClinOncol about the role of KIM-1, the hottest blood biomarker in RCC. With @VincentWenxinXu and Joe Bonventre. nature.com/articles/s4157…

Ab#4543 @ASCO #ASCO26 by @YuWeiChenMD👉bit.ly/4dzu4x9👉High expression of HIF-2α and CA9 identifies a canonical VHL/HIF-driven RCC subtype #kidneycancer👉associated w/⬆️OS & angiogenic and immune gene signatures👇@DrRanaMcKay @OncoAlert @urotoday @KidneyCAN

#ASPIRE trial: Evaluating docetaxel's role in #mHSPC. @deepak_kilari @MedicalCollege & @DrRanaMcKay @UCSanDiego join @neerajaiims @huntsmancancer to discuss the ASPIRE trial, a Phase III study randomizing 1,200 patients with metastatic hormone-sensitive #ProstateCancer to ADT plus apalutamide versus ADT plus apalutamide plus docetaxel. #WatchNow > bit.ly/4mmnxtZ

Advanced #ProstateCancer - First-line #mCRPC/APMR: How do I select the best treatment for my patient? Presentation by @KristineLacuna @MSKCancerCenter. #AUA26 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4dvG9Ui @AmerUrological

A must-read editorial in @EUplatinum 👉ctDNA captures systemic risk, while utDNA fills the local blind spot by detecting bladder recurrence. For bladder-sparing therapy in MIBC, the message is clear: neither biomarker is sufficient alone. 📍Dual-compartment liquid biopsy may be the future of monitoring. @OncoAlert #cancer #oncology @urologysummit doi.org/10.1016/j.euru…

The FDA approves the signatera ctDNA assay for muscle invasive bladder cancer patients post surgery. This is based on the results of Imvigor011 study (atezo vs placebo in ctDNA positives, surveillance for the ctDNA negatives). It opens a new chapter for personalised therapy in urothelial cancer. Focusing on early treatment for those patients that need it and sparing those at lower risk potentially harmful treatment makes sense. ‘It is the first companion diagnostic approval in the field of blood-based MRD.’ natera.com/company/news/s…

VOLGA is positive: perioperative durvalumab + neoadjuvant EV improves EFS and OS in cisplatin-ineligible MIBC. Key difference from KEYNOTE trials: no adjuvant ADC here, only IO. So in pCR patients, is adjuvant ADC really needed? Looking forward for details. @OncoAlert @ONCOassist @Uromigos @tompowles1 @Larvol @MedwatchKate

Honored to stand with @MassGovernor, @DrChoueiri and other members of @DanaFarber team today, as Massachusetts announced major prior authorization reforms. For cancer patients, delays aren’t paperwork. They’re fear, uncertainty, and time. These changes will help patients across Masachusetts access critical care faster and with fewer barriers. Progress matters. Patients matter. Thank you @MassGovernor for putting patients first. 👊👊☘️ @DanaFarberNews @DanaFarber_GU mass.gov/news/governor-…

What great news!!!!! 👏👏👏👏👏👏👏 Perioperative Durvalumab plus EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial. @OncoAlert @seom @CANVES_ES @GUOncologyNow @OncBrothers @myESMO astrazeneca.com/media-centre/p…

Perioperative durvalumab (12 months) with neoadjuvant EV (3 cycles) shows ‘statistically significant and clinically meaningful’ improved EFS and OS vs cystectomy alone in MIBC (like KN905 (EVP cs cystectomy)). The shorter period of EV is the major difference in trial designs. Details of efficacy and toxicity will be important. The 3rd arm, where tremelimumab was added as a triplet, did not hit OS at this stage. astrazeneca.com/media-centre/p… @OncoAlert

Deprioritization of zelenectide pevedotin (nectin-4/MMAE peptide) has occurred in bladder cancer prior to the randomised phase 3 starting (Duravelo-2: 1st line ZP/pembro vs gem/platinum control). The dose finding phase 2 seemed successful (see below) but regulatory feedback questioned the study design - probably the control arm of platinum chemotherapy. EVP is widely established standard of care making it hard to get combos with similar MOA approved. But Randomised phase 3s with EVP as the control (FORAGER-2: Vepugratinib (FGFR3)) are ongoing. @y_loriot @OncoAlert